Evolving Treatment Paradigms for Renal Cell Carcinoma

Evolving Treatment Paradigms for Renal Cell Carcinoma

Episodes

Specialty:

All

Year:

All

EP. 1: Newly Diagnosed Metastatic Renal Cell Carcinoma

July 11th 2018

EP. 2: mRCC Patient Selection for Ipilimumab/Nivolumab

July 11th 2018

EP. 3: mRCC: Cytoreductive Nephrectomy in the Modern Era

July 11th 2018

EP. 4: Risk Stratification for Metastatic Renal Cell Carcinoma

July 11th 2018

EP. 5: Selecting Immunotherapy versus VEGF TKI for mRCC

July 11th 2018

EP. 6: Deferred Therapy for Favorable-Risk mRCC Patients

July 11th 2018

EP. 7: VEGF TKI + Immunotherapy Combinations for mRCC

July 11th 2018

EP. 8: Sunitinib 4/2 vs 2/1 Schedule for Patients with mRCC

July 11th 2018

EP. 9: Disease Progression in Patients with Metastatic RCC

July 11th 2018

EP. 10: Sequencing Approaches in Metastatic Renal Cell Carcinoma

July 11th 2018

EP. 11: Considerations for Using Adjuvant Therapy in mRCC

July 11th 2018

EP. 12: Evolving Treatment Landscape of Renal Cell Carcinoma

July 11th 2018

Trending on OncLive

CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care

Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications

FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS

Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma

NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer